LLY Stock Holds Near $1,374 After Eli Lilly’s Third Guidance Raise
Eli Lilly (LLY) stock is up 1% at $1,373.70 after Q3 2026 revenue rose 39% to $24.4B, beating expectations. The company raised its 2026 revenue guidance to $91B-$92B, the third increase this year. Non-GAAP EPS was $7.48, with guidance at $35-$36. Growth is driven by obesity drugs Mounjaro and Zepbound, but falling prices and research charges are challenges. The company's obesity pill, Foundayo, underperformed expectations. Lilly's stock is seen as a defensive play amid tech sector volatility.
How this was made
The 30-second read
Why it matters
The guidance lift is a primary market‑moving event, likely to keep the stock near recent highs and may attract further buying.
Market read
Lilly's earnings and guidance update are the main catalyst for its stock movement and may influence the broader healthcare sector.
What to watch
One‑time Jardiance milestone revenue and research charge offsets could temper earnings quality.
Background
Eli Lilly's Q3 2026 earnings beat expectations, with 39% revenue growth and a third guidance raise this year.
Ticker impact
Eli Lilly reported Q3 2026 results and raised its 2026 revenue guidance to $91‑$92 B, the third raise this year, driving a 6.6% stock gain.
likely upward pressure as investors price in higher revenue expectations
The new guidance is materially higher than prior expectations and follows a strong earnings beat, suggesting continued buying interest.
Market effects
Biopharma sector may benefit from Lilly's strong obesity‑drug demand, supporting peers.
U.S. market may see modest lift in healthcare indices.
Limited to U.S. equities; no immediate global macro effect.
Counterpoint
Rising volume may mask pricing pressure; falling realized prices could limit upside.
Key entities
- companyEli Lilly
U.S. pharmaceutical company (ticker LLY) reporting earnings and guidance.
